Advertisement

Inflammation Research

, Volume 68, Issue 11, pp 945–955 | Cite as

Anti-angiogenic and anti-inflammatory effects of CD200–CD200R1 axis in oxygen-induced retinopathy mice model

  • Yaguang Hu
  • Ting Wei
  • Shan Gao
  • Qiaochu ChengEmail author
Original Research Paper
  • 146 Downloads

Abstract

Objective

In this study, the expression changes and the potential effects of CD200 and its receptors during the process of retinal neovascularization (RNV) development had been detected, using a classic oxygen-induced retinopathy (OIR) mice model and CD200Fc (a CD200R1 agonist) intravitreal injection.

Materials and methods

7 day postnatal (P7) C57BL/6J mice were raised in hyperoxia incubators with 75±2% oxygen for 5 days, and returned to room air at P12. All animals were subdivided into three groups: normoxia control, OIR, and OIR+CD200Fc group. The mice of OIR+CD200Fc group were intravitreal injected with CD200Fc (2μg/μL, 0.5μL) at P12. Retinas and vitreous samples were harvested at P17. The expression and localization of CD200 and its receptors were analyzed by Western blot, quantitative real-time polymerase chain reaction (qRT-PCR), enzyme-linked immunosorbent assay (ELISA), and retinal whole-mount immunofluorescence. To investigate the effects of CD200Fc treatment, vascular endothelial growth factor (VEGF)-A, platelet-derived growth factor (PDGF)-BB, pro-inflammatory cytokines, NV area, and microglial activation were detected respectively.

Results

In OIR group, both protein and RNA levels of CD200 and CD200R1 were significantly up-regulated. The increased CD200 and CD200R1 were co-localized with Alex594-labeled Griffonia simplicifolia isolectin B4 (IB4) on vascular endothelial cells in NV area of OIR samples, and CD200R1 was co-expressed with ionized calcium-bind adapter molecule 1 (iba1) on microglia in OIR samples at the same time. CD200Fc intravitreal injection could significantly reduce the release of VEGF-A, PDGF-BB, and pro-inflammatory cytokines; shrink the NV area; and inhibit the activation of microglia in OIR mice.

Conclusion

These findings suggested that the up-regulation of CD200 and CD200R1 was closely related to RNV development, and the antiangiogenic effects of CD200Fc in OIR model might be realized by inhibition of inflammatory response and microglia activation. The results may provide a new therapeutic target for RNV diseases.

Keywords

CD200–CD200R1 axis Retinal neovascularization Oxygen-induced retinopathy Inflammatory response Microglia 

Notes

Acknowledgements

This work is supported by the National Natural Science Foundation of China (81600733) and the Institutional Science Foundation of the First Affiliated Hospital of Xi’an Jiaotong University (2017QN-02).

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest.

Ethical approval

All animals involved in experiments were carried out in accordance with the US National Institute of Health (NIH) Guide for the Care and Use of Laboratory Animals published by the US National Academy of Sciences and approved by the Ethics Committee of Xi’an Jiaotong University.

References

  1. 1.
    Kandasamy Y, Hartley L, Rudd D, Smith R. The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review. Br J Ophthalmol. 2017;101(1):21–4.  https://doi.org/10.1136/bjophthalmol-2016-308828.CrossRefGoogle Scholar
  2. 2.
    Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016;44(4):260–77.  https://doi.org/10.1111/ceo.12696.CrossRefGoogle Scholar
  3. 3.
    Xu Y, Lu X, Hu Y, Yang B, Tsui CK, Yu S, Lu L, Liang X. Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1alpha-VEGF pathway in oxygen-induced retinopathy mice. J Pineal Res. 2018;64(4):e12473.  https://doi.org/10.1111/jpi.12473.CrossRefGoogle Scholar
  4. 4.
    Rubio RG, Adamis AP. Ocular angiogenesis: vascular endothelial growth factor and other factors. Dev Ophthalmol. 2016;55:28–37.  https://doi.org/10.1159/000431129.CrossRefGoogle Scholar
  5. 5.
    Cabral T, Mello LGM, Lima LH, Polido J, Regatieri CV, Belfort R Jr, Mahajan VB. Retinal and choroidal angiogenesis: a review of new targets. Int J Retina Vitreous. 2017;3:31.  https://doi.org/10.1186/s40942-017-0084-9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Fiebai B, Odogu V. Intravitreal anti vascular endothelial growth factor agents in the management of retinal diseases: an audit. Open Ophthalmol J. 2017;11:315–21.  https://doi.org/10.2174/1874364101711010315.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Labardini CP, Blumenthal EZ. Causative pathogens in endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Rambam Maimonides Med J. 2018.  https://doi.org/10.5041/rmmj.10348.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Zarubina AV, Gal-Or O, Huisingh CE, Owsley C, Freund KB. Macular atrophy development and subretinal drusenoid deposits in anti-vascular endothelial growth factor treated age-related macular degeneration. Investig Ophthalmol Vis Sci. 2017;58(14):6038–45.  https://doi.org/10.1167/iovs.17-22378.CrossRefGoogle Scholar
  9. 9.
    Leleu I, Penaud B, Blumen-Ohana E, Rodallec T, Adam R, Laplace O, Akesbi J, Nordmann JP. Late and sustained intraocular pressure elevation related to intravitreal anti-VEGF injections: cases requiring filtering surgery. J Fr Ophtalmol. 2018.  https://doi.org/10.1016/j.jfo.2018.07.002.CrossRefGoogle Scholar
  10. 10.
    Eadie BD, Etminan M, Carleton BC, Maberley DA, Mikelberg FS. Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery. JAMA Ophthalmol. 2017;135(4):363–8.  https://doi.org/10.1001/jamaophthalmol.2017.0059.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Zarbin MA. Anti-VEGF agents and the risk of arteriothrombotic events. Asia Pac J Ophthalmol (Phila). 2018;7(1):63–7.  https://doi.org/10.22608/APO.2017495.CrossRefGoogle Scholar
  12. 12.
    Etminan M, Maberley DA, Babiuk DW, Carleton BC. risk of myocardial infarction and stroke with single or repeated doses of intravitreal bevacizumab in age-related macular degeneration. Am J Ophthalmol. 2016;163:53–8.  https://doi.org/10.1016/j.ajo.2015.11.030.CrossRefGoogle Scholar
  13. 13.
    Hanhart J, Comaneshter DS, Freier-Dror Y, Vinker S. Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):651–63.  https://doi.org/10.1007/s00417-018-3917-9.CrossRefGoogle Scholar
  14. 14.
    Rivera JC, Dabouz R, Noueihed B, Omri S, Tahiri H, Chemtob S. Ischemic retinopathies: oxidative stress and inflammation. Oxid Med Cell Longev. 2017;2017:3940241.  https://doi.org/10.1155/2017/3940241.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Altmann C, Schmidt MHH. The role of microglia in diabetic retinopathy: inflammation, microvasculature defects and neurodegeneration. Int J Mol Sci. 2018.  https://doi.org/10.3390/ijms19010110.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Semeraro F, Cancarini A, dell’Omo R, Rezzola S, Romano MR, Costagliola C. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res. 2015;2015:582060.  https://doi.org/10.1155/2015/582060.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tang J, Kern TS. Inflammation in diabetic retinopathy. Progr Retinal Eye Res. 2011;30(5):343–58.  https://doi.org/10.1016/j.preteyeres.2011.05.002.CrossRefGoogle Scholar
  18. 18.
    Rivera JC, Holm M, Austeng D, Morken TS, Zhou TE, Beaudry-Richard A, Sierra EM, Dammann O, Chemtob S. Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies. J Neuroinflammation. 2017;14(1):165.  https://doi.org/10.1186/s12974-017-0943-1.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Barclay AN, Clark MJ, McCaughan GW. Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. Biochem Soc Symp. 1986;51:149–57.Google Scholar
  20. 20.
    Holmannova D, Kolackova M, Kondelkova K, Kunes P, Krejsek J, Andrys C. CD200/CD200R paired potent inhibitory molecules regulating immune and inflammatory responses; part I: CD200/CD200R structure, activation, and function. Acta Medica (Hradec Kralove). 2012;55(1):12–7.  https://doi.org/10.14712/18059694.2015.68.CrossRefGoogle Scholar
  21. 21.
    Gorczynski R, Chen Z, Kai Y, Lee L, Wong S, Marsden PA. CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules. J Immunol. 2004;172(12):7744–9.  https://doi.org/10.4049/jimmunol.172.12.7744.CrossRefGoogle Scholar
  22. 22.
    Hernangomez M, Klusakova I, Joukal M, Hradilova-Svizenska I, Guaza C, Dubovy P. CD200R1 agonist attenuates glial activation, inflammatory reactions, and hypersensitivity immediately after its intrathecal application in a rat neuropathic pain model. J Neuroinflamm. 2016;13:43.  https://doi.org/10.1186/s12974-016-0508-8.CrossRefGoogle Scholar
  23. 23.
    Ren Y, Ye M, Chen S, Ding J. CD200 inhibits inflammatory response by promoting KATP channel opening in microglia cells in Parkinson’s disease. Med Sci Monit. 2016;22:1733–41.  https://doi.org/10.12659/msm.898400.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Varnum MM, Kiyota T, Ingraham KL, Ikezu S, Ikezu T. The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer’s disease. Neurobiol Aging. 2015;36(11):2995–3007.  https://doi.org/10.1016/j.neurobiolaging.2015.07.027.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ren Y, Yang B, Yin Y, Leng X, Jiang Y, Zhang L, Li Y, Li X, Zhang F, He W, Zhang X, Cao X. Aberrant CD200/CD200R1 expression and its potential role in Th17 cell differentiation, chemotaxis and osteoclastogenesis in rheumatoid arthritis. Rheumatology (Oxford). 2015;54(4):712–21.  https://doi.org/10.1093/rheumatology/keu362.CrossRefGoogle Scholar
  26. 26.
    Dick AD, Broderick C, Forrester JV, Wright GJ. Distribution of OX2 antigen and OX2 receptor within retina. Investig Ophthalmol Vis Sci. 2001;42(1):170–6.Google Scholar
  27. 27.
    Singh A, Falk MK, Hviid TV, Sorensen TL. Increased expression of CD200 on circulating CD11b+ monocytes in patients with neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1029–37.  https://doi.org/10.1016/j.ophtha.2012.11.002.CrossRefGoogle Scholar
  28. 28.
    Xu Y, Cheng Q, Yang B, Yu S, Xu F, Lu L, Liang X. Increased sCD200 levels in vitreous of patients with proliferative diabetic retinopathy and its correlation with VEGF and proinflammatory cytokines. Investig Ophthalmol Vis Sci. 2015;56(11):6565–72.  https://doi.org/10.1167/iovs.15-16854.CrossRefGoogle Scholar
  29. 29.
    Taylor S, Calder CJ, Albon J, Erichsen JT, Boulton ME, Morgan JE. Involvement of the CD200 receptor complex in microglia activation in experimental glaucoma. Exp Eye Res. 2011;92(5):338–43.  https://doi.org/10.1016/j.exer.2011.01.012.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Huang R, Lan Q, Chen L, Zhong H, Cui L, Jiang L, Huang H, Li L, Zeng S, Li M, Zhao X, Xu F. CD200Fc attenuates retinal glial responses and RGCs apoptosis after optic nerve crush by modulating CD200/CD200R1 interaction. J Mol Neurosci. 2018;64(2):200–10.  https://doi.org/10.1007/s12031-017-1020-z.CrossRefGoogle Scholar
  31. 31.
    Cox FF, Carney D, Miller AM, Lynch MA. CD200 fusion protein decreases microglial activation in the hippocampus of aged rats. Brain Behav Immun. 2012;26(5):789–96.  https://doi.org/10.1016/j.bbi.2011.10.004.CrossRefGoogle Scholar
  32. 32.
    Smith LE, Wesolowski E, McLellan A, Kostyk SK, D’Amato R, Sullivan R, D’Amore PA. Oxygen-induced retinopathy in the mouse. Investig Ophthalmol Vis Sci. 1994;35(1):101–11.Google Scholar
  33. 33.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods (San Diego, California). 2001;25(4):402–8.  https://doi.org/10.1006/meth.2001.1262.CrossRefGoogle Scholar
  34. 34.
    Zhang L, Xu J, Gao J, Wu Y, Yin M, Zhao W. CD200-, CX3CL1-, and TREM2-mediated neuron-microglia interactions and their involvements in Alzheimer’s disease. Rev Neurosci. 2018.  https://doi.org/10.1515/revneuro-2017-0084.CrossRefGoogle Scholar
  35. 35.
    Rexin P, Tauchert A, Hanze J, Heers H, Schmidt A, Hofmann R, Hegele A. The immune checkpoint molecule CD200 is associated with tumor grading and metastasis in bladder cancer. Anticancer Res. 2018;38(5):2749–54.  https://doi.org/10.21873/anticanres.12517.CrossRefGoogle Scholar
  36. 36.
    Gaiser MR, Weis CA, Gaiser T, Jiang H, Buder-Bakhaya K, Herpel E, Warth A, Xiao Y, Miao L, Brownell I. Merkel cell carcinoma expresses the immunoregulatory ligand CD200 and induces immunosuppressive macrophages and regulatory T cells. Oncoimmunology. 2018;7(5):e1426517.  https://doi.org/10.1080/2162402x.2018.1426517.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Gardner TW, Davila JR. The neurovascular unit and the pathophysiologic basis of diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255(1):1–6.  https://doi.org/10.1007/s00417-016-3548-y.CrossRefGoogle Scholar
  38. 38.
    Horie S, Robbie SJ, Liu J, Wu WK, Ali RR, Bainbridge JW, Nicholson LB, Mochizuki M, Dick AD, Copland DA. CD200R signaling inhibits pro-angiogenic gene expression by macrophages and suppresses choroidal neovascularization. Sci Rep. 2013;3:3072.  https://doi.org/10.1038/srep03072.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Subhi Y, Krogh Nielsen M, Molbech CR, Oishi A, Singh A, Nissen MH, Sorensen TL. CD11b and CD200 on circulating monocytes differentiate two angiographic subtypes of polypoidal choroidal vasculopathy. Investig Ophthalmol Vis Sci. 2017;58(12):5242–50.  https://doi.org/10.1167/iovs.17-22479.CrossRefGoogle Scholar
  40. 40.
    Li L, Eter N, Heiduschka P. The microglia in healthy and diseased retina. Exp Eye Res. 2015;136:116–30.  https://doi.org/10.1016/j.exer.2015.04.020.CrossRefGoogle Scholar
  41. 41.
    Jiang L, Xu F, He W, Chen L, Zhong H, Wu Y, Zeng S, Li L, Li M. CD200Fc reduces TLR4-mediated inflammatory responses in LPS-induced rat primary microglial cells via inhibition of the NF-kappaB pathway. Inflamm Res. 2016;65(7):521–32.  https://doi.org/10.1007/s00011-016-0932-3.CrossRefGoogle Scholar
  42. 42.
    Liu C, Shen Y, Tang Y, Gu Y. The role of N-glycosylation of CD200–CD200R1 interaction in classical microglial activation. J Inflamm. 2018.  https://doi.org/10.1186/s12950-018-0205-8.CrossRefGoogle Scholar
  43. 43.
    Oria M, Figueira RL, Scorletti F, Sbragia L, Owens K, Li Z, Pathak B, Corona MU, Marotta M, Encinas JL, Peiro JL. CD200–CD200R imbalance correlates with microglia and pro-inflammatory activation in rat spinal cords exposed to amniotic fluid in retinoic acid-induced spina bifida. Sci Rep. 2018;8(1):10638.  https://doi.org/10.1038/s41598-018-28829-5.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Checchin D, Sennlaub F, Levavasseur E, Leduc M, Chemtob S. Potential role of microglia in retinal blood vessel formation. Investig Ophthalmol Vis Sci. 2006;47(8):3595–602.  https://doi.org/10.1167/iovs.05-1522.CrossRefGoogle Scholar
  45. 45.
    Ebneter A, Kokona D, Schneider N, Zinkernagel MS. microglia activation and recruitment of circulating macrophages during ischemic experimental branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 2017;58(2):944–53.  https://doi.org/10.1167/iovs.16-20474.CrossRefGoogle Scholar
  46. 46.
    Xu W, Wu Y, Hu Z, Sun L, Dou G, Zhang Z, Wang H, Guo C, Wang Y. Exosomes from microglia attenuate photoreceptor injury and neovascularization in an animal model of retinopathy of prematurity. Mol Ther Nucleic Acids. 2019;16:778–90.  https://doi.org/10.1016/j.omtn.2019.04.029.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Ding X, Gu R, Zhang M, Ren H, Shu Q, Xu G, Wu H. Microglia enhanced the angiogenesis, migration and proliferation of co-cultured RMECs. BMC Ophthalmol. 2018.  https://doi.org/10.1186/s12886-018-0886-z.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of OphthalmologyThe First Affiliated Hospital of Xi’an Jiaotong UniversityXi’anChina

Personalised recommendations